SpliceBio
$135Mlatest round · Series B · Jun 2025 · 17 mo ago
4backers · Asabys Partners, NEA
200+team · employees, estimated range
23stories in the press
Key facts
These are the key facts about SpliceBio on Alion as of Nov 13, 2026. The latest round is Series B of $135M, announced in 2025.
- Employees
- 200+Alion company profile, an estimated range
- Total raised
- $135MSum of 1 equity round Alion knows
- Latest round
- Series B · $135M · Jun 11, 2025Press report · marketwatch.com
Funding and backers
Total raised
$135M
1 round on record
Latest round
$135M
Series B · Jun 2025 · 17 mo ago
Team
201-500
employees, estimated range
Backers
4
Asabys Partners, NEA
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 6
New executive SpliceBio Appoints Don Munoz as Chief Financial Officer · splice.bio
Jun 11, 2025
Raised a round Series B $135M
Jan 3, 2024
New executive SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer · splice.bio
Jun 20, 2023
New executive SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program · splice.bio
Sep 2020
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jun 2025 | $135M | — | marketwatch.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs ExpressionEdits
backs Averna Therapeutics
Similar startupsby what they do, their industry and backers
Hyku Biosciences is developing the next generation of small molecule medicines by targeting histidine, tyrosine and lysine binding pockets…
Carmine Therapeutics is pioneering a powerful new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs).
Averna Therapeutics is creating the last, great missing tool required to break through the most persistent barriers in genetic medicine.
Kelonia is revolutionizing gene delivery to expand the impact of genetic medicines; built on decades of research, development, and…
Getting genetic syntax right.. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make…
Developing the next generation of left-heart access technologies.
Financials
Total raised
$135M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2025 | $135M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Asabys PartnersVia a fund
Novartis Venture FundVia a fund
Ysios CapitalVia a fund
NEAVia a fund
672 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation, following previously received Orphan
Read more
Report
SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
Read more
Report
SpliceBio Appoints Don Munoz as Chief Financial Officer
BARCELONA, January 06, 2026 - SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer. Mr. Munoz, who
Read more
Report
SpliceBio: $135 Million Series B Raised For Expanding Pipeline Of Genetic Medicines
SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the closing of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventu
Read more
Report
SpliceBio: $135 Million Series B Secured For Advancing Lead Program SB-007
SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the closing of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventu
Read more
Report
SpliceBio lands $135M for a new kind of eye gene therapy
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
Read more
Report
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
/PRNewswire/ -- SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today...
Read more
Report
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi V
Read more
Report
SpliceBio gathers $135m for eye disease gene therapies
Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
Read more
Report
Show more news
How to cite this page
Alion, "SpliceBio: key facts", as of Nov 13, 2026. https://alion.io/company/splice-bio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0